Psychedelics Today

In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of Psychedelic Science 2025. Based in Vancouver, Mattha has written for The Guardian, VICE, Esquire, TIME, and Wired, bringing a uniquely embedded yet critical lens to the space. They discuss the post-conference mood and the sense that the industry is sobering up—less hype, more introspection. Mattha reflects on the growing division between underground practitioners, activists, and biotech startups, and the importance of vision, ethics, and scrutiny in the midst of this cultural moment. Other topics include: * Ketamine overuse and dependence, especially in social and parenting contexts * The future of psychedelic nightlife, harm reduction, and mocktail bars * Gender and sexual fluidity as uncovered through psychedelics * Questions of IP, underground wisdom, and psychedelic ownership * Psychedelics as tools for peacebuilding, especially in conflict zones * The shadow side of spiritual experiences and how to spot bad actors * The value of pleasure, intimacy, and human connection in the psychedelic journey Joe and Mattha also reflect on the resurgence of psychedelic use in Texas, the legacy of the Stark Club, and how Christian libertarianism and military trauma might influence unexpected policy changes. This conversation is bold, honest, funny, and thoughtful—exactly the kind of cultural critique the movement needs right now. Find Mattha on Instagram at @matthamundo [http://instagram.com/matthamundo] and on LinkedIn at Mattha Busby [https://www.linkedin.com/in/mattha-busby-60a64165/]. His new pocketbook on drug policy is available now.

Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom [https://www.mindbloom.com], one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art. The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom’s outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions. Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need. If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain. Resources: * Mindbloom.com [https://www.mindbloom.com] * Vital Psychedelic Training [https://www.vitalpsychedelictraining.com]

In this episode, we sit down with Victoria Litman, M.Div., J.D., LL.M [https://law.rwu.edu/faculty/victoria-litman]., to discuss why the future of psychedelic access in the United States is being shaped not by federal agencies, but by the bold actions of individual states. As a legal scholar and writer focusing on drug policy, Victoria breaks down the significance of the FDA’s 2024 rejection of psychedelic-assisted therapy, and why that decision might be less of a setback than it seems. We explore how state-level initiatives like Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are setting the stage for a new model of access—one rooted in harm reduction, personal liberty, and existing regulatory infrastructure. Victoria discusses the importance of the Tenth Amendment and the Anti-Commandeering Doctrine, which allow states to move forward regardless of federal inaction. Rather than waiting for slow-moving federal institutions, Victoria argues that states can build safe, scalable systems now—especially by leveraging cannabis infrastructure for psychedelic regulation. She also touches on the ethical and cultural implications of this transition, including protections for spiritual and religious use. If you’re wondering what psychedelic policy will look like in the years ahead, this episode offers an insightful and hopeful roadmap. Link to CATO article [http://In%20this%20episode,%20we%20sit%20down%20with%20Victoria%20Litman,%20M.Div.,%20J.D.,%20LL.M.,%20to%20discuss%20why%20the%20future%20of%20psychedelic%20access%20in%20the%20United%20States%20is%20being%20shaped%20not%20by%20federal%20agencies,%20but%20by%20the%20bold%20actions%20of%20individual%20states.%20As%20a%20legal%20scholar%20and%20writer%20focusing%20on%20drug%20policy,%20Victoria%20breaks%20down%20the%20significance%20of%20the%20FDA%E2%80%99s%202024%20rejection%20of%20psychedelic-assisted%20therapy,%20and%20why%20that%20decision%20might%20be%20less%20of%20a%20setback%20than%20it%20seems.%20We%20explore%20how%20state-level%20initiatives%20like%20Oregon%E2%80%99s%20Psilocybin%20Services%20Act%20and%20Colorado%E2%80%99s%20Natural%20Medicine%20Health%20Act%20are%20setting%20the%20stage%20for%20a%20new%20model%20of%20access%E2%80%94one%20rooted%20in%20harm%20reduction,%20personal%20liberty,%20and%20existing%20regulatory%20infrastructure.%20Victoria%20discusses%20the%20importance%20of%20the%20Tenth%20Amendment%20and%20the%20Anti-Commandeering%20Doctrine,%20which%20allow%20states%20to%20move%20forward%20regardless%20of%20federal%20inaction.%20Rather%20than%20waiting%20for%20slow-moving%20federal%20institutions,%20Victoria%20argues%20that%20states%20can%20build%20safe,%20scalable%20systems%20now%E2%80%94especially%20by%20leveraging%20cannabis%20infrastructure%20for%20psychedelic%20regulation.%20She%20also%20touches%20on%20the%20ethical%20and%20cultural%20implications%20of%20this%20transition,%20including%20protections%20for%20spiritual%20and%20religious%20use.%20If%20you%E2%80%99re%20wondering%20what%20psychedelic%20policy%20will%20look%20like%20in%20the%20years%20ahead,%20this%20episode%20offers%20an%20insightful%20and%20hopeful%20roadmap.]

Joe Moore and Anne Philippi are hosts of the PS25 Morning Show! This one features Dee Dee Goldpaugh, LCSW and Tommaso Barba, PhDC! We talk about all things Sex and Psychedelics!

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world’s leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.  Trevor shares his early work supporting marginalized populations in Vancouver’s Downtown Eastside, which led to the founding of Liberty Root, one of Canada’s first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: * The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. * Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. * Ambio’s groundbreaking neuroregenerative program for Parkinson’s, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. * How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford’s 2024 study on Special Forces veterans. * Why ibogaine isn’t just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. * The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. * Their cautionary perspective on Texas’ $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn’t just part of the movement; it’s the blueprint for how ibogaine could be delivered worldwide. Links: * Ambio Website: https://ambio.life/ [https://ambio.life/] * Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1535782/full] (Frontiers in Immunology, Feb 2025) * Magnesium–ibogaine therapy in veterans with traumatic brain injuries [https://www.nature.com/articles/s41591-023-02705-w] (Nature Medicine, Jan 2024) * Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion [https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2023.1256396/full] (Frontiers in Pain Research, Aug 2023) * Novel treatment of opioid use disorder using ibogaine and iboga in two adults [https://akjournals.com/view/journals/2054/4/3/article-p149.xml] (Journal of Psychedelic Studies, Jan 2020) * Clinical Guidelines for Ibogaine-Assisted Detoxification [https://ibogaineguidelines.com/] * Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions [https://markets.businessinsider.com/news/stocks/ambio-life-sciences-launches-world-s-first-clinical-ibogaine-program-for-patients-with-neurodegenerative-conditions-1034806038] Bios:  Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world’s leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field’s foundational safety guidelines and has published widely on ibogaine’s therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine’s potential for trauma, TBI, pain, MS, and Parkinson’s. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine’s applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.